Breast cancer begins in the breast, typically as a ductal carcinoma and can affect men or women. It is the second most commonly diagnosed cancer of women in the United States. Risk for developing breast cancer increases with age, family history, gene mutations on BRCA1 and BRCA2, obesity, radiation exposure, early onset of puberty, never having kids, postmenopausal hormone therapy, and excessive alcohol intake. Treatment for breast cancer includes: surgery, radiation therapy, chemotherapy, hormone therapy, alternative medicine, and various medications. Bilateral breast cancer occurs when the cancer has developed in both breasts. Research indicates that the 10-year recurrence rate for stage I bilateral breast cancer is nearly twice as high as that of stage I unilateral breast cancer.
Bilateral Breast Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Bilateral Breast Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 2265 products for the study of Bilateral Breast Cancer that can be applied to Chromatin Immunoprecipitation, Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.
Bilateral Breast Cancer is also known as bilateral breast cancer, bilateral breast carcinoma.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.